US court orders Boehringer to disclose AmAb launch plans

Feb 27, 2019

In ongoing litigation between Boehringer and AbbVie, the court has ordered Boehringer to release its plans for biosimilar adalimumab, Cytelzo®. Cytelzo® has been approved by the FDA but has not yet been launched.

Print Page Mail Article